Publications by authors named "Omotola O Olasupo"
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Cochrane Database Syst Rev
February 2024
Background: Management of congenital hemophilia A and B is by prophylactic or on-demand replacement therapy with clotting factor concentrates. The effects of newer non-clotting factor therapies such as emicizumab, concizumab, marstacimab, and fitusiran compared with existing standards of care are yet to be systematically reviewed.
Objectives: To assess the effects (clinical, economic, patient-reported, and adverse outcomes) of non-clotting factor therapies for preventing bleeding and bleeding-related complications in people with congenital hemophilia A or B compared with prophylaxis with clotting factor therapies, bypassing agents, placebo, or no prophylaxis.
Background: The development of antibodies (inhibitors) to clotting factors compromises the management of hemophilia A and B, resulting in resistance to clotting factor replacement and, in many cases, the need for bypassing agents to achieve hemostasis.
Objectives: To evaluate the association between the presence of inhibitors and achievement of perioperative hemostasis, development of complications, and presurgical plan deviations.
Methods: We conducted a retrospective study using data from the Indiana Hemophilia and Thrombosis Center surgical database (1998-2019).
Cytisine for smoking cessation: A systematic review and meta-analysis.
Drug Alcohol Depend
October 2023
Background: Cytisine is a smoking cessation medication. This systematic review incorporates recently published randomized controlled trials (RCTs) to provide an updated evidence-based assessment of cytisine's efficacy and safety.
Methods: We searched Cochrane Library, MEDLINE, and EMBASE, for RCTs comparing cytisine to other smoking cessation treatments in adults who smoke.
Article Synopsis
- The Indiana Hemophilia and Thrombosis Center (IHTC) developed a surgical database to analyze surgeries performed on patients with bleeding disorders from 1998 to 2019.
- A total of 3,246 procedures were conducted on 1,413 patients, primarily involving minor surgeries, with a 90.9% success rate in achieving proper blood clotting before and during surgery.
- The study highlighted that while complications occurred in 13.6% of surgeries, the effectiveness of hemostasis improved over the years, indicating the database's potential to enhance surgical management and inform future patient care practices.
Background: The hallmark of severe hemophilia (A or B) is recurrent bleeding into joints and soft tissues with progressive joint damage, despite on-demand treatment. Prophylaxis has long been used, but not universally adopted, because of medical, psychosocial, and cost controversies.
Objectives: To determine the effectiveness of clotting factor concentrate prophylaxis in managing previously-treated individuals with hemophilia A or B.